Korea’s Boryung Signs MOU To Sell Kanarb In Turkey, Algeria, Kazakhstan
This article was originally published in PharmAsia News
Executive Summary
South Korea’s Boryung cuts another deal for angiotensin receptor anatagonist Kanarb, following a similar deal for Central and South America.